Interview with Petr Tor, Country Director, Stallergenes Czech Republic
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
Address: Belgicka 20 – 120 00 Praha 2 ,Czech Republic
Tel: +420 222 515 342
Web: http://www.stallergenes.cz/
Stallergenes is a European biopharmaceutical company specialised in the treatment by allergen immunotherapy of allergy related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates nearly 20% (gross) of its sales to its Research and Development activities, which are primarily directed at developing a new therapeutic range: sublingual immunotherapy tablets. In 2011, the company had sales of € 235 million and more than 500,000 patients were treated with Stallergenes products.
Sublingual immunotherapy tablets
NPPs
Diagnosis products
Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did…
A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s orphan drug legislation as no standard pathway…
Jiří Lukeš, of B Braun Czech Republic, introduces the success of the affiliate he helped establish over 27 years ago, and why he feels that the local business is doing…
Petr Vaculík, country manager of PSI CRO, a privately owned Swiss clinical research organization (CRO), describes how the number of clinical trials is decreasing in the Czech Republic, although many…
Tamer Shawky, general manager Central Region for J&J Medical Devices, shares his first expectations arriving into the region three years ago, following a successful career in the Middle East and…
Olga Starobová, medical director of Syneos Health Czech Republic, walks us through the steps put in place to ensure successful synergies during the merger between INC Research and InVentiv Health,…
Kostas Deligiannis, general manager Eastern Europe for GE Healthcare (GEHC), outlines GE Healthcare’s commitment to the 20-country region under his remit, his priorities for greater collaboration between these countries, and…
Paul-François Cossa, country chair of Sanofi Czech Republic & Slovakia and General Manager CHC, reviews the outstanding performance of the company in 2019, breaks down his new vision for Sanofi…
Pavla Rozmarová, clinical research associate manager & regional OD for the Czech affiliate of German CRO Scope International, describes how the Czech clinical research landscape has evolved in the past…
Roman Badik, CEO of Enantis, the first biotechnology spin-off from Masaryk University in the Czech Republic, shares his vision of turning the company’s research breakthroughs into a self-sustaining business. Badik…
Augustin Bernát, general manager for the Czech affiliate of ResMed, a company whose cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases, discusses how…
Among the seven insurance funds in the Czech Republic, VZP is the largest with six million clients and the widest network of health service providers. David Šmehlík, the organisation’s deputy…
Martin Puchwein, country president for Novartis Group Czech Republic, and general manager for pharma, shares his perspectives on launching innovative drugs in the country, including some new therapeutic approaches such…
See our Cookie Privacy Policy Here